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INTRODUCTION
Autoimmune hepatitis is a chronic necro-inflammatory
hepatitis of unknown etiology. It is characterized by auto-
antibodies that target against liver-specific and non-organ-
specific antigens (1). Corticosteroids, especially prednisone
or prednisolone (PD), have been the key drugs of initial anti-
inflammatory and immuno-suppressive therapy of autoim-
mune hepatitis in children (2). However, it is well known
that long-term use of corticosteroid is associated with the risk
of steroid-induced toxicities, and this requires newer immuno-
suppressive agents for the treatment of autoimmune hepatitis,
especially in growing children. 
We report on the case of a 11-yr-old Korean girl with type-
1 autoimmune hepatitis who discontinued PD due to steroid-
induced toxicities, but who remained in biochemical and clin-
ical remission while undergoing deflazacort and ursodeoxy-
cholic acid (UDCA) combination therapy.
CASE REPORT
A 9-yr-old girl was admitted to Eul-Ji Hospital because
of jaundice and right upper quadrant pain. Her height was
135 cm (75-90 percentile), and weight was 43 kg (over 97
percentile). The sclera was icteric, and the liver edge descended
4 cm below the right costal margin. The results of laborato-
ry studies were as follows: aspartate aminotransferanse (AST)
1,106 IU/L, alanine aminotransferase (ALT) 1,888 IU/L, total
bilirubin 25.7 mg/dL, direct bilirubin 18.2 mg/dL, total pro-
tein 6.9 g/dL, albumin 4.2 g/dL, serum alkaline phosphatase
1,160 IU/L, GGTP 71 IU/L, INR 2.4, aPTT >120 sec, anti-
nuclear antibody (ANA) (+) speckled pattern, with 1:320 titer,
anti-smooth muscle antibody (Ab) (-), anti- mitochondrial
(AMA Ab) (-), IgG 1,397 mg/dL, anti-HAV IgM (-), anti-HBc
IgM (-), HbsAg (-), EBV-VCA IgG/M (-/-), and ceruloplasmin
28 mg/dL. Liver biopsy results showed piecemeal necrosis at the
portal-lobular interface accompaning mild to moderate infil-
tration of lymphocytes, moderate centrilobular cholestasis,
moderate lobular inflammation, and moderate fibrosis (Fig. 1).
According to the scoring system of International Autoimmune
Hepatitis Group (3), she had definite autoimmune hepatitis
(score=16). Initially, on 40 mg of PD and 300 mg of UDCA
daily, she gradually recovered both clinically and biochemi-
cally. PD was tapered gradually, and three months later, she
was taking 15 mg of PD and 300 mg of UDCA daily. At eight
months, her aminotransferase level had elevated to 400 IU/L,
but reduced rapidly when PD was increased to 40 mg/day.
At nine months, she was taking 15 mg/day of PD and 300
mg/day of UDCA, but she complained of hirsutism, striae,
moon face, and buffalo hump, at ten months. The results of
a second round of laboratory studies conducted at this time
were; AST 21 IU/L, ALT 52 IU/L, total bilirubin 0.7 mg/dL,
total protein 7.2 g/dL, albumin 4.7 g/dL, glucose 86 mg/dL,
ANA (+) speckled pattern, with 1:160 titer. Accordingly,
deflazacort (Calcort
�, HanDok Pharm Co., Ltd, Eumseong-
goon, Chungcheongbuk-do, Korea) was administered at dose
of 18 mg a day, instead of PD at dose of 18 mg a day, and
UDCA was continued. Her biochemical test remained with-
in normal ranges on this regimen, and the PD-associated com-
plications improved rapidly. Fourteen months later, deflazacort
was reduced at dose of 15 mg a day, and after 19 months of
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Deflazacort for Type-1 Autoimmune Hepatitis in a Korean Girl
Prednisone or prednisolone are the mainstay drug treatments for autoimmune hep-
atitis in children. However, long-term use of corticosteroid is associated with the risk
of steroid-induced toxicities, and this situation requires newer immuno-suppressive
agents for the treatment of autoimmune hepatitis, especially in growing children. An
11-yr-old Korean girl with type-1 autoimmune hepatitis discontinued prednisolone
due to toxicities, i.e., hirsutism, buffalo hump, and skin striae, and remained clinical
and biochemical remission under replacement of deflazacort and ursodeoxycholic
acid combination therapy. A follow-up liver biopsy after 19 months of deflazacort
and ursodeoxycholic acid treatment showed histologic remission.
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deflazacort treatment, a follow-up liver biopsy was performed.
This showed no lobular activity, no portal activity, near-nor-
mal periportal inflammation, and fibrosis (Fig. 2). ANA test-
ing at this time also yielded a negative result (Fig. 3). Deflaza-
cort was discontinued after 25 months and UDCA was dis-
continued a few months after this. The girl has been in clin-
ical and biochemical remission for two years now, without
therapy.
DISCUSSION
There are few diseases to be differentiated from autoim-
mune hepatitis, overlap syndrome, in which the features of
autoimmune hepatitis is combined with those of primary
biliary cirrhosis, or primary sclerosing cholangitis, and autoim-
mune cholangitis. In overlap with primary biliary cirrhosis,
serologic test of AMA is usually positive and histologic study
shows findings of cholangitis. In overlap with primary scle-
rosing cholangitis, serologic test of AMA is negative, and
histologic evidence suggests various forms of cholangitis. In
autoimmune cholangitis, serologic test of AMA is negative,
and histologic examination shows bile duct injury, suggestive
of primary biliary cirrhosis. Autoimmune cholangitis, also, is
generally not steroid-responsive. In the present case, despite
the cholestatic presentation, serum level of GGTP was not
so high, histologic study showed no evidence of definite cho-
langitis, and response to steroid was excellent. According to
the scoring system of International Autoimmune Hepatitis
Group, this case has definite autoimmune hepatitis (pre-treat-
ment score 16, post-treatment score 18).
The long-term use of corticosteroid is known to be associ-
ated with the risk of steroid-induced toxicities. Generally,
there are several ways of reducing steroid-associated toxici-
ties, i.e., administering steroid on an alternate-day schedule,
administering adjunctive agent to reduce the need for steroid,
and finding a substitute agent. However, of these three options
in case of autoimmune hepatitis, the risk of relapse is higher
if steroids are administered on an alternate-day schedule (4),
and thus this method is not recommended. Some authors add
Fig. 1. The pre-treatment liver biopsy shows moderate-lobular in-
flammation and mild portal inflammation (H&E, ×100). The inset
shows piecemeal necrosis and moderate fibrosis (H&E, ×400).
Fig. 3. Clinical course of the patient. The patient manifested fulmi-
nent hepatitis with ANA positivity and a normal IgG level. Initially,
a conventional steroid (prednisolone) and ursodeoxycholic acid
was tried. After the development of steroid toxicities, deflazacort
(Calcort
�) was substituted for prednisolone. The patient remained
on clinical and biochemical remission, and ANA became negative.
A follow-up liver biopsy was performed. 
T.B, total bilirubin; UDCA, ursodeoxycholic acid; ANA, antinucle-
ar antibody.
Fig. 2. Post-treatment liver biopsy shows no lobular activity, and
no portal activity (H&E, ×100). The inset shows near-normal peri-
portal inflammation and fibrosis in the portal area (H&E, ×200).
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azathioprine to steroids if normalization of the liver function
is not obtained by steroids alone or if too high a dose of steroids
is required to maintain normal transaminase levels (4). Initial
combination therapy with steroid and azathioprine, is con-
sidered by some authors as standard therapy of autoimmune
hepatitis in children, as in adults (1). However, there is con-
cern about the oncogenecity associated with long-term aza-
thioprine therapy (5), and because of its hepatotoxicity, some
authors do not recommend azathioprine as first line treatment,
particularly in severely jaundiced patients (4). Thus, UDCA
was prescribed as an adjuvant medication with PD or deflaza-
cort. In a clinical study on Japanese adults, UDCA improved
aminotransferase levels and reduced inflammation in liver
biopsy (6); however, a clinical study on Caucasian adults showed
no significant difference in the results of biochemical tests
or in histologic indices between a UDCA group and a placebo
group (7). Thus, the role of UDCA in autoimmune hepati-
tis warrants further study.
Deflazacort is a synthetic steroid, an oxazoline derivative
of PD, with potentially lower toxicities than prednisone or
PD (8), and has been widely used as an immunosuppressant
in the field of pediatric nephrology; nephrotic syndrome and
renal transplantation (9), and in Duchenne dystrophy (10).
Only one case of adult study has indicated that deflazacort
might be a suitable substitute for PD in the treatment of
autoimmune hepatitis (11). In clinical trials in Spain, deflaza-
cort was administered to patients with type-1 autoimmnune
hepatitis who were in remission on a stable dose of PD. Only
clinical and biochemical remission were maintained during
the follow-up period without histologic examination. In the
present case, deflazacort was substituted for PD as a therapeu-
tic drug in a child who was in remission on PD and UDCA,
but significant PD-associated toxicities occurred. After switch-
ing to deflazacort, these toxicities improved rapidly, and the
patient remained in clinical and biochemical remission. After
19 months on deflazacort, a follow-up liver biopsy showed
near-normalization of auto-immune hepatitis. This is the first
known clinical report to show that deflazacort is a suitable
substitute for PD in the treatment of autoimmune hepatitis.
Clinical and biochemical remission in this case were support-
ed by documented histologic resolution. 
A recent study showed the measurement of organ- and non-
organ-specific auto-antibodies and IgG levels correlated with
disease activity in autoimmune hepatitis (12). The patient
in the present case remained ANA- positive with 1:160 titer,
when on PD and UDCA, but became ANA negative at about
the time of the follow-up liver biopsy performed after 19
months on deflazacort and UDCA. This may provide addi-
tional evidence that deflazacort is a possible substitute for PD
in the treatment of autoimmune hepatitis. This case poses
the possibility that deflazacort can be a possible substitute
for prednisone in type-1 autoimmune hepatitis in children,
and demonstrates the need for further study.
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